Quick Answer
Neumora Therapeutics, Inc. reported Net Income Loss of -$236.93 million for the year ending 2025.
- Neumora Therapeutics, Inc. showed an increase of +2.8% in Net Income Loss from 2024 to 2025.
- This data is from Neumora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Neumora Therapeutics, Inc.'s Net Income Loss has declined by 81.0%.
- Historical annual values: Fiscal year 2025: -$236.93 million | Fiscal year 2024: -$243.79 million | Fiscal year 2023: -$235.93 million | Fiscal year 2022: -$130.90 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: